Daunomycinon | 27932-89-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 并四苯
• 英文名称: Daunomycinon
• 英文别名: Daunorubicin aglycone；9-acetyl-6,7,9,11-tetrahydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione
• CAS: 27932-89-4
• 化学式: C₂₁H₁₈O₈
• 分子量: 398.369
• InChiKey: YOFDHOWPGULAQF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  29
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  141
• 氢给体数：
  4
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  Daunomycinon 生成 (3-acetyl-3-acetyloxy-5,12-dihydroxy-10-methoxy-6,11-dioxo-2,4-dihydro-1H-tetracen-1-yl) acetate
  参考文献：
  名称：

  HANSEN, D. W. (JR);PAPPO, R.;GARLAND, R. B., J. ORG. CHEM., 53,(1988) N 18, C. 4244-4253

  摘要：

  DOI：
• 作为产物：
  描述：

  6,7-Di-O-methyl-daunomycinon 以66%的产率得到
  参考文献：
  名称：

  HASSALL, C. H.;BROADHURST, M. J

  摘要：

  DOI：

文献信息

• Anthracycline Derivatives For Treating Tumor Diseases
  申请人：Produkem Molekulares Design GmbH

  公开号：US20150252069A1

  公开（公告）日：2015-09-10

  The invention relates to compounds of the general formula (I) in which R 1 is a hydrogen atom, a hydroxy or methoxy group, a halogen atom, or an NO 2 group; R 2 is a hydrogen atom, a hydroxy or methoxy group, or an acyl or aroyl group; R 3 is hydrogen, trifluoroacetyl (C(═O)CF 3 ), or p-nitrobenzoyl (C(═O)PhNO 2 ), and in each case the wavy line represents both possible configurations of —OR 3 relative to the skeleton; Y is [C(═O)], [C(═N)—OH], [CH—OH], or [CH—NR 5 R 6 ] in the two possible stereoisomer arrangements, wherein R 5 and R 6 either each represent a hydrogen atom or a hydrogen atom and a trifluoroacetyl group (TFA); X=O, S, or NR, in which R=hydrogen or a C 1 to C 4 alkyl group; and R 4 is an unbranched or branched alkyl or heteroalkyl chain with a chain length of 1 to 19 elements, maximally 6 heteroatoms (O, N, S) being separated from one another in any combination by at least two carbon atoms. The invention further relates to, among others, methods for producing the compounds according to formula (I), to pharmaceutical compositions, to a pharmaceutical kit, and to the use thereof as a medicament for treating proliferative diseases or conditions, preferably cancer.

  本发明涉及通式(I)的化合物，其中R1是氢原子、羟基或甲氧基、卤素原子或NO2基团；R2是氢原子、羟基或甲氧基、酰基或芳酰基；R3是氢、三氟乙酰基(C(═O)CF3)或对硝基苯甲酰基(C(═O)PhNO2)，并且每次波浪线代表相对于骨架的—OR3的两种可能构型；Y是[C(═O)]、[C(═N)—OH]、[CH—OH]或[CH—NR5R6]，在两种可能的立体异构体排列中，其中R5和R6各自代表氢原子或氢原子和三氟乙酰基(TFA)基团；X=O、S或NR，其中R=氢或C1至C4烷基；R4是无分支或有分支的烷基或杂烷基链，链长为1至19个元素，最多6个杂原子(O、N、S)以任何组合彼此至少由两个碳原子隔开。本发明还涉及，其中包括，根据通式(I)的化合物的制备方法、药物组合物、药物套件及其作为药物用于治疗增生性疾病或状况，特别是癌症的用途。
• Processes for producing doxorubicin, daunomycinone, and derivatives of doxorubicin
  申请人：The Board of Regents of the University of Nebraska

  公开号：EP0523289A1

  公开（公告）日：1993-01-20

  To produce doxorubicin and its analogues, methyl 3alpha, 5alpha-dihydroxy-5beta-(trimethylsilylethynyl)-2alpha-nitromethylcyclohexane-1beta-carboxylate acetonide is condensed with 1,4-dihydro-4,4,5-trimethoxy-1-oxonaphthalene in the presence of 1,8-diazabicyclo-[5.4.0]undec-7-ene in an aprotic solvent to produce 3-[(2beta-carbomethoxy-4beta-ethynyl-4alpha, 6alpha-(di-0-isopropylidenyl)cyclohexanyl-1-yl]-nitromethyl-4,4,5-trimethoxy-1-oxo-1,2,3,4-tetrahydronaphthalene, which is cyclized to produce 9beta-ethynyl-12-hydroxy-7alpha,9alpha-(di-0-isopropylidenyl)-6-nitro-4,5,5-trimethoxy-5,5a,6,6a,7,8,9,10,10a,11-decahydro-11-naphthacenone. The decahydro-11-naphthacenone is converted to 7alpha-9alpha,(di-0-isopropylidenyl)-4,5-dimethoxy-9beta-ethynyl-12-hydroxy-6-nitro-6,6a,7,8,9,10,10a,11-octahydro-11,-naphthacenone. The octahydro-11-naphthacenone is oxidized to 7alpha-9alpha, (di-0-isopropylidenyl)-9beta-ethynyl-11-hydroxy-4-methoxy-6-nitro-7,8,9,10,-tetrahydro-5,12-naphthacenedione which is converted to 6-desoxy-6-nitrodaunomycinone, daunomycinone and related 6-substituted analogues of daunomycinone.

  为了生产阿霉素及其类似物，需要将甲基3α，5α-二羟基-5β-(三甲基硅乙炔基)-2α-硝基甲基环己烷-1β-羧酸乙酸酯与1,4-二氢-4,4,5-三甲氧基-1-氧代萘醌在无极性溶剂中，在1,8-二氮杂双环[5.4.0]十一烷-7-烯的存在下进行缩合反应，产生3-[(2β-羧甲氧基-4β-乙炔基-4α，6α-(二异丙亚基)环己基-1-基]-硝基甲基-4,4,5-三甲氧基-1-氧代-1,2,3,4-四氢萘烯，然后将其环化产生9β-乙炔基-12-羟基-7α，9α-(二异丙亚基)-6-硝基-4,5,5-三甲氧基-5,5a,6,6a,7,8,9,10,10a,11-十氢-11-萘酮。 十氢-11-萘酮转化为7α-9α，(二异丙亚基)-4,5-二甲氧基-9β-乙炔基-12-羟基-6-硝基-6,6a,7,8,9,10,10a,11-八氢-11-萘酮。 八氢-11-萘酮氧化为7α-9α，(二异丙亚基)-9β-乙炔基-11-羟基-4-甲氧基-6-硝基-7,8,9,10,-四氢-5,12-萘醌，然后转化为6-去氧-6-硝基多柔霉素酮，多柔霉素酮及相关的多柔霉素酮6-取代物。
• Method of preparing 4-R-substituted 4-demethoxydaunorubicin
  申请人：——

  公开号：US20040236086A1

  公开（公告）日：2004-11-25

  A method of synthesizing 4-R-substituted anthracyclines and their corresponding salts from 4-demethyldaunorubicin includes the steps of treating 4-demethyldaunorubicin with a sulfonylating agent to form 4-demethyl-4-sulfonyl-R 3 -daunorubicin. 4-Demethyl-4-R 3 -sulfonyl-daunorubicin is then subject to a reducing agent in the presence of a transition metal catalyst in a temperature range of about 30° C. to about 100° C. in a polar aprotic solvent in an inert atmosphere. Protected 4-demethoxy-4-R-daunomycin then undergoes hydrolysis in a basic solution to form the 4-R-substituted anthracyclines. The novel method lacks the step of forming a stereospecific glycoside bond between aglycone and aminoglycoside. The method also increases the yield of the final product up to 30 to 40%.

  一种从4-去甲基多柔比星合成4-R-取代蒽环素及其相应盐的方法，包括以下步骤：用磺酰化试剂处理4-去甲基多柔比星，形成4-去甲基-4-磺酰基-R3-多柔比星。然后，在惰性气氛下，在极性无水溶剂中，在约30℃至约100℃的温度范围内，用过渡金属催化剂对4-去甲基-4-R3-磺酰基-多柔比星进行还原。保护的4-去甲氧基-4-R-多柔霉素然后在碱性溶液中经过水解，形成4-R-取代蒽环素。这种新方法省略了在缺乏立体特异性的情况下形成脱糖基和氨基糖苷之间的立体特异性糖苷键的步骤。该方法还将最终产物的产率提高了30%至40%。
• METHOD OF PRODUCING 4-DEMETHOXYDAUNORUBICIN
  申请人：Zabudkin Alexander

  公开号：US20120277415A1

  公开（公告）日：2012-11-01

  The present invention relates to a method for the synthesis of 4-demethoxydaunorubicin (idarubicin) having the chemical structure of formula (I), which involves the demethylation of 3′-Prot-daunorubicin in the presence of a soft Lewis acid. The method of the present invention does not comprise cleavage of the glycosidic linkage at carbon C7, thus resulting in a faster synthesis cycle and an improved yield of the final product.

  本发明涉及一种合成4-去甲氧基多柔红霉素（伊达霉素）的方法，其化学结构如式（I），该方法涉及在软性Lewis酸存在下对3'-Prot-多柔红霉素进行去甲基化。本发明的方法不包括在碳C7处断裂糖苷键，因此导致合成周期更快，最终产物的产率提高。
• METHOD FOR PREPARING 4-DEMETHYLDAUNORUBICIN
  申请人：Zabudkin F. Alexander

  公开号：US20070135624A1

  公开（公告）日：2007-06-14

  A method of preparing the anthracyclin carminomycin using a starting material comprising daunorubicin. The method comprises reacting daunorubicin or N-protected daunorubicin with soft Lewis acids for the demethylation of the 4-methoxy group, resulting in a reaction mass. The reaction mass is treated with an aqueous solution of a strong organic acid or a mineral acid. After decomposition of the resulting carminomycin and Lewis acids reactive complex, the reaction mass is extracted using a water insoluble organic solvent. As a result, carminomycin is extracted as a base.

  使用含有多柔比星的起始物质制备蒽环类卡米诺霉素的方法。该方法包括将多柔比星或N-保护的多柔比星与软路易斯酸反应，以去甲基化4-甲氧基团，形成反应混合物。将反应混合物与强有机酸或矿物酸的水溶液处理。在分解产生的卡米诺霉素和路易斯酸反应复合物后，使用水不溶性有机溶剂提取反应混合物。结果，卡米诺霉素以碱的形式被提取。